Abstract:Abstract Background Our previous studies have reported the down-regulation of EGFL8 correlates to the development and prognosis of colorectal and gastric cancer. The present study is carried out to explore the expression pattern and role of EGFL8 in hepatocellular carcinoma (HCC). Methods and materials EGFL8 expression in 102 cases of HCC tissues matched with adjacent non-tumorous liver tissues, a normal liver cell line and three liver cancer cell lines with different metastatic capacity was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blot. Moreover, the clinicopathological features and prognosis of HCC patients were correlated with expression of EGFL8. Subsequently, the gain-and loss-of-function experiments were carried out to investigate the biological function of EGFL8 in HCC. We also used N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-(S)- phenylglycine t-butyl ester (DAPT), an inhibitor for Notch signaling pathway, in these experiments to verify the involvement of Notch signaling pathway in the effects of EGFL8. Additionally, a mouse model was established to investigate the effect of EGFL8 on metastasis of HCC cells. The expression of Notch signaling pathway in HCC cells and xenograft mouse tumors were detected by Western blot and immunohistochemistory. Results The expression of EGFL8 was significantly decreased in HCC tissues and cell lines and EGFL8 down-regulation correlated to multiple nodules, vein invasion, high TNM stage and poor prognosis of HCC. Interestingly, the expression levels of EGFL8 in three liver cancer cell lines were negatively associated with their metastatic capacity. In vitro and in vivo experiments indicated that EGFL8 obviously suppressed metastasis and invasion of HCC cells but slightly promoted apoptosis. Meanwhile, the expression of Notch signaling pathway was obviously suppressed in EGFL8 overexpressed HCCLM3 cells and xenograft mouse tumors generated from these cells but markedly elevated in EGFL8 depleted Hep3B cells. Furthermore, the up-regulated expression of Notch signaling pathway and effects induced by EGFL8 knockdown in Hep3B cells could be counteracted by DAPT treatment. Conclusion The down-regulation of EGFL8 was correlated to progression and poor prognosis of HCC and regulates HCC cell migration, invasion and apoptosis through activating the Notch signaling pathway, suggesting EGFL8 as a novel therapeutic target and a potential prognostic marker for HCC.

LncRNA Meg8 Suppresses Activation of Hepatic Stellate Cells and Epithelial-Mesenchymal Transition of Hepatocytes Via the Notch Pathway

LncRNA MEG8 Plays an Oncogenic Role in Hepatocellular Carcinoma Progression Through Mir-367-3p/14-3-3ζ/tgfβr1 Axis.

Regulatory Long Non-Coding RNAs of Hepatic Stellate Cells in Liver Fibrosis (Review)

LncRNA-MEG3 inhibits activation of hepatic stellate cells through SMO protein and miR-212

Inhibitory Effects of Long Noncoding RNA MEG3 on Hepatic Stellate Cells Activation and Liver Fibrogenesis.

LncRNA-SNHG7/miR-29b/DNMT3A Axis Affects Activation, Autophagy and Proliferation of Hepatic Stellate Cells in Liver Fibrosis.

Lncrna-Nef Regulates Hepatic Stellate Cells Proliferation, Cell Cycle, Apoptosis and ECM Synthesis Through the ERK1/2/c-Fos Axis

MicroRNA-146b Regulates Hepatic Stellate Cell Activation Via Targeting of KLF4.

The liver-enriched lnc-LFAR1 promotes liver fibrosis by activating TGFβ and Notch pathways

MicroRNA-708 Represses Hepatic Stellate Cells Activation and Proliferation by Targeting ZEB1 Through Wnt/β-catenin Pathway.

LncRNA MEG3 reverses CCl4-induced liver fibrosis by targeting NLRC5

The Hepatocyte-Specifically Expressed Lnc-Hser Alleviates Hepatic Fibrosis by Inhibiting Hepatocyte Apoptosis and Epithelial-Mesenchymal Transition.

Down-regulation of EGFL8 regulates migration, invasion and apoptosis of hepatocellular carcinoma through activating Notch signaling pathway

Up‐regulation of FUT8 Inhibits TGF-β1-induced Activation of Hepatic Stellate Cells During Liver Fibrogenesis

LncRNA Airn Maintains LSEC Differentiation to Alleviate Liver Fibrosis Via the KLF2-eNOS-sGC Pathway

MicroRNA-708 Modulates Hepatic Stellate Cells Activation and Enhances Extracellular Matrix Accumulation Via Direct Targeting TMEM88.

LncRNA Snhg12/IGFBP3 axis is involved in liver fibrosis by promoting the proliferation and activation of mouse hepatic stellate cells

The M6a Methyltransferase Mettl3 Deficiency Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis

LncRNA-Gm9866 promotes liver fibrosis by activating TGFβ/Smad signaling via targeting Fam98b

LncRNA H19-EZH2 interaction promotes liver fibrosis via reprogramming H3K27me3 profiles

Hepatocyte‐derived exosomes deliver the lncRNA CYTOR to hepatic stellate cells and promote liver fibrosis